v3.25.0.1
Licensing, Acquisitions, and Other Arrangements (Details) - ImmunoGen - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
5 Months Ended 11 Months Ended 12 Months Ended
Feb. 12, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition            
Payments to Acquire Businesses, Net of Cash Acquired       $ 17,493 $ 0 $ 255
Goodwill   $ 34,956 $ 34,956 34,956 32,293 32,156
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized     $ 510      
Amortization of intangible assets       7,622 7,946 $ 7,689
Business Acquisition, Pro Forma Revenue       56,389 54,691  
Business Acquisition, Pro Forma Net Income (Loss)       $ 4,564 $ 2,862  
RSUs            
Business Acquisition            
Granted (in shares)   300 300 600    
ImmunoGen            
Business Acquisition            
Cash per share received by shareholders (in dollars per share) $ 31.26          
Cash consideration paid $ 9,800          
Payments to Acquire Businesses, Net of Cash Acquired 9,200          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents 591          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables 171          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 211          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other 40          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment 7          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Product Rights 7,200          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, License agreements 125          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development 1,280          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets 273          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt (99)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable (312)          
Deferred tax liabilities (899)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other (47)          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net 8,541          
Goodwill 1,249          
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net 9,790          
Fair value step-up adjustment to inventories 179          
Intangible assets - Developed product rights 7,300          
Intangible assets - In-process research and development $ 1,300          
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 12 years          
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets $ 250          
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual     $ 578      
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual     (682)      
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized     349      
Inventory fair value step-up amortization     179      
Amortization of intangible assets     157      
ImmunoGen | Selling, general and administrative            
Business Acquisition            
Business Combination, Acquisition Related Costs     $ 59